JP2023513720A - 感染症の治療又は発症を制限するためのポリペプチド、組成物、及びそれらの使用 - Google Patents

感染症の治療又は発症を制限するためのポリペプチド、組成物、及びそれらの使用 Download PDF

Info

Publication number
JP2023513720A
JP2023513720A JP2022548783A JP2022548783A JP2023513720A JP 2023513720 A JP2023513720 A JP 2023513720A JP 2022548783 A JP2022548783 A JP 2022548783A JP 2022548783 A JP2022548783 A JP 2022548783A JP 2023513720 A JP2023513720 A JP 2023513720A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
protein
rbd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513720A5 (https=
Inventor
キング，ニール，ピー．
ヴィ―スラー，デイヴィット
ウォーキー，カール
ウォールズ，アレクサンドラ，シー．
ワン，ジン，ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of JP2023513720A publication Critical patent/JP2023513720A/ja
Publication of JP2023513720A5 publication Critical patent/JP2023513720A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022548783A 2020-02-14 2021-02-12 感染症の治療又は発症を制限するためのポリペプチド、組成物、及びそれらの使用 Pending JP2023513720A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062977036P 2020-02-14 2020-02-14
US62/977,036 2020-02-14
US202063046159P 2020-06-30 2020-06-30
US63/046,159 2020-06-30
US202063064235P 2020-08-11 2020-08-11
US63/064,235 2020-08-11
PCT/US2021/017799 WO2021163438A1 (en) 2020-02-14 2021-02-12 Polypeptides, compositions, and their use to treat or limit development of an infection

Publications (2)

Publication Number Publication Date
JP2023513720A true JP2023513720A (ja) 2023-04-03
JP2023513720A5 JP2023513720A5 (https=) 2024-02-19

Family

ID=74873805

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548783A Pending JP2023513720A (ja) 2020-02-14 2021-02-12 感染症の治療又は発症を制限するためのポリペプチド、組成物、及びそれらの使用

Country Status (13)

Country Link
US (1) US20240277831A1 (https=)
EP (1) EP4103230A1 (https=)
JP (1) JP2023513720A (https=)
KR (1) KR20220142472A (https=)
CN (1) CN116096404A (https=)
AU (1) AU2021221139A1 (https=)
BR (1) BR112022016220A2 (https=)
CA (1) CA3167318A1 (https=)
CO (1) CO2022011467A2 (https=)
MX (1) MX2022009860A (https=)
PE (1) PE20230301A1 (https=)
PH (1) PH12022552099A1 (https=)
WO (1) WO2021163438A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
JP2023521418A (ja) 2020-04-10 2023-05-24 インビビド， インコーポレイテッド コロナウイルスｓタンパク質に特異的な化合物及びその使用
WO2022016122A2 (en) * 2020-07-17 2022-01-20 Tonix Pharmaceuticals Holding Corp. Skin-based testing for detection of cell-mediated immune responses to sars-cov-2
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
US20220324918A1 (en) * 2021-03-30 2022-10-13 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF
WO2023034991A1 (en) * 2021-09-02 2023-03-09 Kansas State University Research Foundation Mrna vaccine formulations and methods of using the same
US20240385189A1 (en) * 2021-09-10 2024-11-21 Jacobs Technion-Cornell Institute Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions
KR102527221B1 (ko) * 2021-10-15 2023-05-02 에스케이바이오사이언스 주식회사 단백질의 정제방법
KR102621026B1 (ko) * 2021-10-15 2024-01-09 에스케이바이오사이언스(주) 단백질의 정제방법
KR102524839B1 (ko) * 2021-11-04 2023-04-25 에스케이바이오사이언스(주) 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
US20250000968A1 (en) * 2021-11-12 2025-01-02 The United States of America, as represented by the Secretary,Department of Health and Human Service Sars-cov-2 spike fused to a hepatitis b surface antigen
WO2023122257A2 (en) * 2021-12-22 2023-06-29 La Jolla Institute For Immunology Coronavirus spike glycoprotein with improved expression and stability
CN114656571B (zh) * 2022-02-18 2024-07-16 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种四价SARS-CoV-2嵌合纳米颗粒疫苗及其制备方法与应用
US20240207389A1 (en) * 2022-04-27 2024-06-27 Northwestern University Methods for improving covid vaccine immunogenicity
WO2024014943A1 (ko) * 2022-07-12 2024-01-18 에스케이바이오사이언스 주식회사 Sars-cov-2 백신 부스터 조성물
WO2024076982A2 (en) * 2022-10-05 2024-04-11 University Of Washington Pan-sarbecovirus nanoparticle vaccines
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160122392A1 (en) * 2014-11-03 2016-05-05 University Of Washington Polypeptides for use in self-assembling protein nanostructures
JP2016539944A (ja) * 2013-11-26 2016-12-22 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 新規ｓａｒｓ免疫原性組成物
WO2018187325A1 (en) * 2017-04-04 2018-10-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017887B1 (ru) * 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
US10248758B2 (en) * 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US10676511B2 (en) * 2015-09-17 2020-06-09 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
WO2018175560A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
WO2019169120A1 (en) * 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539944A (ja) * 2013-11-26 2016-12-22 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 新規ｓａｒｓ免疫原性組成物
US20160122392A1 (en) * 2014-11-03 2016-05-05 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2018187325A1 (en) * 2017-04-04 2018-10-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Accession No.MN908947.1", DATABASE GENBANK, JPN6025013417, 12 January 2020 (2020-01-12), ISSN: 0005745917 *

Also Published As

Publication number Publication date
PH12022552099A1 (en) 2024-01-29
CA3167318A1 (en) 2021-08-19
MX2022009860A (es) 2022-11-07
US20240277831A1 (en) 2024-08-22
EP4103230A1 (en) 2022-12-21
AU2021221139A1 (en) 2022-09-01
PE20230301A1 (es) 2023-02-13
KR20220142472A (ko) 2022-10-21
CO2022011467A2 (es) 2022-10-31
CN116096404A (zh) 2023-05-09
BR112022016220A2 (pt) 2022-10-25
WO2021163438A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
JP2023513720A (ja) 感染症の治療又は発症を制限するためのポリペプチド、組成物、及びそれらの使用
Walls et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
US20250171500A1 (en) Conformationally stabilized rsv pre-fusion f proteins
Más et al. Engineering, structure and immunogenicity of the human metapneumovirus F protein in the postfusion conformation
CN102939096B (zh) 用于预防和治疗流感病毒疾病的疫苗
CN116096733A (zh) Covid-19融合蛋白的抗原特异性免疫疗法和使用方法
CN118480560B (zh) 呼吸道合胞病毒mRNA疫苗及其制备方法和应用
US9701720B2 (en) Epitope-scaffold immunogens against respiratory syncytial virus (RSV)
CN108430502A (zh) 诺瓦克病毒疫苗
HK40094028A (zh) 多肽、组合物及其用於治疗或限制感染发展的用途
US20260069679A1 (en) Coronavirus spike protein-based vaccines
US20250161436A1 (en) Multivalent vaccine for paramyxoviruses and uses thereof
RU2844177C2 (ru) Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение
Dosey Engineering influenza HA nanoparticles to better understand their immune responses and improve vaccine design

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260226